Parametric Portfolio Associates LLC boosted its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 354,011 shares of the biopharmaceutical company’s stock after purchasing an additional 682 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.16% of Alexion Pharmaceuticals worth $46,368,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Avestar Capital LLC grew its holdings in Alexion Pharmaceuticals by 10.7% in the first quarter. Avestar Capital LLC now owns 836 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 81 shares during the period. We Are One Seven LLC grew its holdings in Alexion Pharmaceuticals by 5.7% in the second quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 86 shares during the period. Institutional & Family Asset Management LLC grew its holdings in Alexion Pharmaceuticals by 39.5% in the first quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 87 shares during the period. YorkBridge Wealth Partners LLC grew its holdings in Alexion Pharmaceuticals by 15.4% in the first quarter. YorkBridge Wealth Partners LLC now owns 696 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 93 shares during the period. Finally, Signaturefd LLC grew its holdings in Alexion Pharmaceuticals by 13.2% in the second quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 96 shares during the period. Hedge funds and other institutional investors own 93.23% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Goldman Sachs Group restated a “neutral” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a report on Thursday, May 23rd. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 24th. Credit Suisse Group decreased their price objective on shares of Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Thursday, August 15th. Finally, Leerink Swann set a $157.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $160.44.

Shares of ALXN stock traded down $0.86 on Friday, hitting $107.40. The stock had a trading volume of 1,087,405 shares, compared to its average volume of 3,195,241. The firm has a market capitalization of $24.27 billion, a price-to-earnings ratio of 15.15, a P/E/G ratio of 1.03 and a beta of 1.67. The stock’s 50 day moving average is $109.85 and its 200-day moving average is $124.51. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04. Alexion Pharmaceuticals, Inc. has a 52-week low of $92.56 and a 52-week high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.07 earnings per share. Equities analysts expect that Alexion Pharmaceuticals, Inc. will post 9.03 earnings per share for the current year.

In other news, insider Aradhana Sarin sold 578 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $132.00, for a total value of $76,296.00. Following the completion of the transaction, the insider now directly owns 30,201 shares in the company, valued at $3,986,532. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the transaction, the executive vice president now owns 29,627 shares of the company’s stock, valued at $3,933,873.06. The disclosure for this sale can be found here. 4.08% of the stock is currently owned by corporate insiders.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Is it Safe to Invest in Commodities?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.